EVFM - Evofem Biosciences, Inc. Summary, Stock Quote and News | Benzinga

Market Overview

6.410 -0.23 (-3.46%)

Data as of Dec 05, 2019

Prev. Close 6.64
Price Open 6.51
Volume 153,799
Day's Range 6.0301 - 6.56
52 Wk Range 3.1601 - 7.5
50 Day Moving Avg. 5.35
PE Ratio 0
Shares Outstanding 46.81M
Market Cap 300.06M

Trade EVFM stock with recommended broker Ally Invest. Commissions as low as $3.95.

Analyst Rating View All Ratings

The Daily Biotech Pulse: Astellas To Buy Audentes For $3B, Applied Genetics Chief Medical Officer Quits, Axsome Aces Midstage Trial Shanthi RexalineTue, 03 Dec 2019 07:59:26 -0500
75 Biggest Movers From Yesterday Lisa LevinTue, 03 Dec 2019 05:48:48 -0500
44 Stocks Moving In Monday's Mid-Day Session Lisa LevinMon, 02 Dec 2019 12:11:02 -0500
Stocks That Hit 52-Week Highs On Monday Lisa LevinMon, 02 Dec 2019 10:15:26 -0500
Evofem Biosciences shares are trading higher after the company's phase 2b study of Amphora for the prevention of Chlamydia and Gonorrhea met its primary and secondary endpoints. Benzinga NewsdeskMon, 02 Dec 2019 07:30:02 -0500
10 Healthcare Stocks Moving In Monday's Pre-Market Session Lisa LevinMon, 02 Dec 2019 07:24:13 -0500
Evofem Biosciences' Phase 2b Study of Amphora for Prevention of Chlamydia and Gonorrhea Met Primary and Secondary Endpoints Benzinga NewsdeskMon, 02 Dec 2019 06:51:32 -0500
Evofem Biosciences Reports Resubmission Of New Drug Application To FDA For Amphora For Prevention Of Pregnancy Benzinga NewsdeskTue, 26 Nov 2019 07:40:45 -0500
The Week Ahead In Biotech: Aquestive Awaits FDA Decision, Arrowhead Earnings And More Shanthi RexalineSun, 24 Nov 2019 16:19:59 -0500
Evofem Biosciences Q3 EPS $(0.3) Beats $(0.31) Estimate Benzinga NewsdeskWed, 06 Nov 2019 16:57:21 -0500
{{ story.title }} {{ story.author }}{{ story.created }}

Show more Loading articles...

PDL BioPharma Congratulates Evofem Biosciences on Achieving Major Regulatory and Clinical Milestones with its Lead Product Candidate Amphora® PRNewswire2 days ago
Evofem Biosciences Reports Positive Top-Line Results from Phase 2b Study of Amphora® for Prevention of Chlamydia and Gonorrhea in Women PRNewswire3 days ago
Evofem Biosciences Resubmits New Drug Application to U.S. FDA for Amphora® for the Prevention of Pregnancy PRNewswireNov 26, 2019
Evofem Biosciences' CEO Saundra Pelletier Awarded 2019 Business Woman Of The Year PRNewswireNov 14, 2019
Evofem Biosciences to Participate in Upcoming Investor Conferences PRNewswireNov 13, 2019
Evofem Biosciences Reports Third Quarter 2019 Financial Results and Provides Corporate Update PRNewswireNov 06, 2019
Evofem Biosciences to Report Third Quarter 2019 Results and Provide Corporate Update on November 7, 2019 PRNewswireOct 24, 2019
Evofem Biosciences to Present at Cantor Global Healthcare Conference on October 4, 2019 PRNewswireSep 25, 2019
Microbiotica Appoints Thomas Lynch as Independent Non-Executive Chairman Business WireSep 25, 2019
Evofem Biosciences Completes Phase 2b 'AMPREVENCE' Trial of Amphora for Prevention of Chlamydia and Gonorrhea in Women PRNewswireAug 26, 2019
{{ story.title }} {{ story.author }}{{ story.created }}

Show more Loading articles...

Evofem Biosciences (EVFM) Presents At Piper Jaffray Healthcare Conference - Slideshow Seeking Alpha8 min ago
SKT, CLVS among premarket gainers Seeking Alpha3 days ago
Evofem up 24% premarket on positive Amphora data in STD prevention Seeking Alpha3 days ago
Evofem Bio resubmits NDA for Amphora Seeking AlphaNov 26, 2019
Evofem Biosciences, Inc. (EVFM) CEO Saundra Pelletier on Q3 2019 Results - Earnings Call Transcript Seeking AlphaNov 10, 2019
PDL BioPharma (PDLI) Q3 Earnings Beat, LENSAR Drives Sales ZacksNov 07, 2019
Evofem Biosciences (EVFM) Investor Presentation - Slideshow Seeking AlphaSep 05, 2019
Evofem Bio completes mid-stage AMPREVENCE trial for prevention of chlamydia and gonorrhea in women Seeking AlphaAug 26, 2019
Evofem To Bring A Unique Product To Growing Market Seeking AlphaAug 16, 2019
Evofem Biosciences, Inc. (EVFM) CEO Saundra Pelletier on Q2 2019 Results - Earnings Call Transcript Seeking AlphaAug 10, 2019
{{ story.title }} {{ story.author }}{{ story.created }}

Show more Loading articles...

Earnings View Earnings

Q3 2019	EST	Actual	Surprise
EPS:	-0.310	-0.300	0.0100
Rev:		0.00

Q4 2019	EST	Actual	Surprise
EPS:	Expected 2020-02-28
Rev:	Expected 2020-02-28

Company Profile

Read More

Brokerage Center

Compare All Online Brokerages

Book A Demo

Learn How You Can Succeed In The Market With Benzinga Pro

Fastest Market News

Real-Time News Alerts

Customizable News Filters

Book A Demo